Company news
Scynexis, Inc. news in 2025
Scynexis, Inc.'s news releases, calls and decks from 2025, newest first.
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
December 22, 2025
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
November 19, 2025
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
November 17, 2025
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 5, 2025
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
October 15, 2025
SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
September 30, 2025
SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
September 4, 2025
SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
August 25, 2025
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 13, 2025
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
May 28, 2025
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 15, 2025
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
April 8, 2025
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
March 12, 2025